Tissue heart valves market seen reaching $1.72 billion by 2030

The tissue heart valves market is projected to rise from $1.52 billion in 2025 to $1.72 billion by 2030, driven by aging populations, cardiovascular disease growth and wider use of transcatheter procedures. North America led the market in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - Tissue heart valves are a key option for patients who need valve replacement but may not be suited for mechanical valves. - Market growth signals rising demand for cardiac surgery devices as cardiovascular disease rates climb and healthcare systems expand access to treatment. - The shift toward bioprosthetic and minimally invasive valve procedures could reshape how hospitals treat valve disease.

What happened: - The tissue heart valves market was valued at $1.52 billion in 2025 and is projected to reach $1.56 billion in 2026. - The market is forecast to climb to $1.72 billion by 2030, implying a 2.5% CAGR from 2026 to 2030. - The report links recent growth to cardiovascular disease, mechanical valve limitations, wider surgical valve replacement use, stronger hospital cardiac infrastructure and aging populations. - The report identifies the expanding use of transcatheter aortic valve replacement, or TAVR, as a major growth driver in the next several years. - The Business Research Company released the report, titled "Tissue Heart Valves Market Report 2026 – Market Size, Trends, And Global Forecast 2026-2035." - The report offers a free sample and the full market report.

The details: - Tissue heart valves are biological valves made from animal or human tissue and used to replace damaged heart valves during surgery. - Tissue valves are designed to mimic natural valve function more closely than mechanical valves. - The valves are described as biocompatible and less thrombogenic, which can reduce the need for long-term anticoagulation therapy. - The report says key forecast-period trends include growing preference for bioprosthetic valves, more transcatheter valve procedures, improvements in tissue preservation, less long-term anticoagulant use and more demand for replacements tied to aging. - The report says growth in minimally invasive cardiac surgery, better valve durability, improved healthcare access and more cardiology specialization will also support the market. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region over the forecast period. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report includes market attractiveness scoring, TAM analysis, company scoring matrices, Excel-based forecasting dashboards, hotspot infographics, technology trends and updated graphics and tables.

Between the lines: - The forecast suggests tissue heart valves remain a mature but steadily expanding market rather than a high-growth category. - The strongest demand appears tied to aging demographics and the spread of less invasive cardiac procedures, not a single disruptive breakthrough. - The regional split points to established demand in North America and faster catch-up growth in Asia-Pacific as healthcare investment rises. - In September 2024, the Heart Failure Society of America said about 6.7 million Americans age 20 and older were living with heart failure, with that figure projected to rise to 8.7 million by 2030.

What's next: - The report expects the market to continue growing through 2030 as TAVR adoption, surgical innovation and broader healthcare access increase. - Demand should also rise as the burden of cardiovascular disease and heart failure expands in older populations. - The company is promoting expert contact channels for buyers seeking more detail on the report and its forecasts.

The bottom line: - Tissue heart valves are on a slow but steady growth path, supported by an aging patient base and wider use of minimally invasive heart procedures.